Pep Club Launches Telehealth Platform Offering Prescription Peptide Protocols
Thursday, July 2nd, 2026 - Pep Club, a direct-to-consumer telehealth company co-founded by entrepreneur Greg Yuna and Gabriel Yuna, announced Wednesday the launch of a platform combining prescription therapy, peptide protocols, and at-home biomarker testing. The New York-based company said the service aims to provide personalized treatment plans that include FDA-approved medications alongside compounded peptide therapies prescribed through licensed clinicians.
The platform offers patients access to at-home testing kits that measure biomarkers including hormone levels, inflammation markers, and metabolic indicators, according to the company's announcement. Results are reviewed by affiliated healthcare providers who may recommend treatment protocols that include peptides such as BPC-157, thymosin alpha-1, and others commonly used off-label for recovery, immune support, and anti-aging purposes.
Regulatory context remains unsettled
The launch comes amid heightened scrutiny of the peptide market. The FDA has not approved most peptides marketed through telehealth platforms for the conditions they are commonly prescribed for, including tissue repair, cognitive enhancement, or longevity. Compounded peptide products are not subject to the same premarket review as FDA-approved drugs, and regulators have issued warning letters to compounding pharmacies and telehealth companies for marketing unapproved products.
The FDA's compounding advisory committee, which includes members with ties to the peptide industry, is currently reviewing policies that could reshape how compounded peptides are regulated. The agency has also determined that the shortage of tirzepatide—a dual GIP/GLP-1 drug—has been resolved, which may limit compounding pharmacies' ability to produce copycat versions.
Safety warnings persist
Independent health experts have repeatedly warned that unregulated peptide products carry risks including contamination, incorrect dosing, and unknown long-term effects. Australian doctors recently issued overdose warnings after testing revealed double-strength retatrutide in products marketed for weight loss. Women have been specifically cautioned about grey-market peptides used for fertility, with concerns about where injections are administered and product sterility.
Sports anti-doping rules remain separate
Athletes considering peptide therapies should verify current World Anti-Doping Agency rules, which prohibit peptide hormones, growth factors, and related substances. The WADA prohibited list includes many peptides commonly marketed through telehealth platforms, and athletes risk sanctions for using them without therapeutic use exemptions.
Related reading
- /tracker/ for ongoing regulatory updates on compounded GLP-1 drugs
- /regulatory/fda-warning-letters-tracker/ for enforcement actions against peptide marketers
- /clinical-review-methodology/ for how Medriva evaluates peptide research claims
